Center for Cancer Experimental Therapeutics

癌症实验治疗中心

• 批准号: 8303357
• 负责人: BARBARA N TIMMERMANN
• 金额: $ 109.23万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8303357
• 关键词: Accounting; Affinity; Area; Award; Basic Cancer Research; Biochemical; Biology; Books; Cancer Center; Cells; Centers of Research Excellence; Cities; Collaborations; Complex; Data; Drug Compounding; Educational workshop; Ensure; Funding; Goals; Grant; Housing; Human Resources; Journals; Kansas; Label; Laboratories; Malignant Neoplasms; Manuscripts; Mentors; Mission; Pharmaceutical Chemistry; Phase; Pilot Projects; Program Research Project Grants; Publishing; Request for Applications; Research; Research Personnel; Research Project Grants; Research Support; Screening procedure; Services; Small Interfering RNA; Therapeutic; United States National Institutes of Health; Universities; Work; analog; anticancer research; base; design; drug discovery; experience; high throughput screening; indexing; instrumentation; meetings; novel; professor; programs; square foot; structural biology; tool

In this application we are requesting funds to continue our COBRE Center for Cancer Experimental Therapeutics (CCET) for five more years. Our center was among the first group of COBRE grants awarded in 2000. The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas. It has been a very successful program (http://ccet.cobre.ku.edu/index.php). During the first ten years of the program our center has funded 26 full Project Awards and 27 smaller First Awards. Thirty tenure track assistant professors have received funding. Of these, 11 have been promoted with tenure and 12 are still on the tenure track. The CCET investigators have obtained 42 NIH-funded grants (17 R01s) and 37 grants from other agencies, leading to a total of about $36,500,000 in new funding to Kansas. These investigators have published 218 journal and book manuscripts on research supported by the CCET. An essential part of our COBRE program was the establishment of two research cores, a High Throughput Screening (HTS) Core and a Medicinal Chemistry (MDC) Core. The COBRE Cores are located in the Structural Biology Center (SBC) located on the University of Kansas West Campus. The modern 4,500 sq.ft. High Throughput Screening Core research/office complex is fully equipped with state-of-the-art instrumentation and the personnel have extensive experience in executing cell-based, biochemical, label-free, siRNA as well as high content screening campaigns. The primary goal of the HTS Core has been to make modern drug discovery tools available to biomedical researchers in the Greater Kansas City area, Kansas and beyond. The equally modern Medicinal Chemistry Core is housed in a laboratory of approximately 2000 square feet. The MDC Core works in conjunction with the HTS Core and in collaboration with COBRE investigators and other researchers. The tasks of the MDC Core are (1) to perform synthesis of known compounds necessary for biochemical studies, (2) to design and synthesize novel drug compounds as probes for ongoing studies, (3) to work with the HTS Core and its biology collaborators in carrying out optimization of hits obtained in screening campaigns, and (4) to synthesize fluorescent or affinity tagged analogs of existing probes when necessary for cell localization or target identification studies. In this Phase III application we are requesting funds to continue these successful research cores and to make them self-sustaining by the end of the five-year funding. In addition, we seek funding to support a Pilot Project program to help basic cancer research investigators obtain preliminary data to strengthen their applications to agencies for major funding. We plan to fund four projects per year. Finally, we request support for an Administrative Core to oversee the entire program, including the Pilot Project program and the two research cores.

在此应用中，我们要求资金继续我们的癌症实验治疗中心（CCET）五年。我们的中心是2000年授予的第一批毛绒赠款之一。CCET的任务是增加堪萨斯州与癌症相关的研究和NIH资金。这是一个非常成功的程序（http://ccet.cobre.ku.edu/index.php）。在该计划的前十年中，我们的中心资助了26个完整的项目奖和27个较小的第一奖。三十个任期助理教授已经获得了资金。其中，有11个被任命晋升，而12个仍在统治轨道上。 CCET调查人员已获得42个NIH资助的赠款（17 R01）和37个来自其他机构的赠款，从而向堪萨斯州获得了约36,500,000美元的新资金。这些调查人员已经发布了218个有关CCET支持的研究的期刊和书籍手稿。 我们的毛线计划的重要组成部分是建立了两个研究核心，高吞吐量筛查（HTS）核心和药物化学（MDC）核心。索伯岩岩心位于堪萨斯大学西部校园的结构生物学中心（SBC）。现代4,500平方英尺高通量筛选核心研究/办公室综合体完全配备了最先进的仪器，并且人员在执行基于细胞的，生化，无标签，siRNA以及高内容筛选活动方面具有丰富的经验。 HTS核心的主要目标是使堪萨斯州，堪萨斯州及其他地区的生物医学研究人员可用现代药物发现工具。 同样现代的药物化学核心位于大约2000平方英尺的实验室中。 MDC核心与HTS核心合作，并与COBRE研究人员和其他研究人员合作。 The tasks of the MDC Core are (1) to perform synthesis of known compounds necessary for biochemical studies, (2) to design and synthesize novel drug compounds as probes for ongoing studies, (3) to work with the HTS Core and its biology collaborators in carrying out optimization of hits obtained in screening campaigns, and (4) to synthesize fluorescent or affinity tagged analogs of existing probes when necessary for cell本地化或目标识别研究。在此阶段III申请中，我们要求资金继续这些成功的研究核心，并在五年资金结束之前使它们自我维持。此外，我们寻求资金支持试点项目计划，以帮助基本的癌症研究研究人员获得初步数据，以加强对代理商进行大量资金的应用。我们计划每年为四个项目提供资金。最后，我们要求支持管理核心来监督整个计划，包括试点项目计划和两个研究核心。